scispace - formally typeset
Search or ask a question

Showing papers in "Vaccine in 2004"


Journal ArticleDOI
13 Aug 2004-Vaccine
TL;DR: Systematic evaluation of M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys revealed protection against lethal challenge of either H1N1 or H3N1 virus in mice and the ability to reduce viral shedding in the lower respiratory tracts of mice and ferrets.

354 citations


Journal ArticleDOI
09 Sep 2004-Vaccine
TL;DR: The aim of the present review is to put the recent findings into a broader perspective to facilitate the application of these adjuvants in general and experimental vaccinology.

337 citations


Journal ArticleDOI
13 Aug 2004-Vaccine
TL;DR: A systematic attempt has been made to develop a direct method for predicting CTL epitopes from an antigenic sequence based on quantitative matrix (QM) and machine learning techniques such as Support Vector Machine (SVM) and Artificial Neural Network (ANN).

327 citations


Journal ArticleDOI
02 Jan 2004-Vaccine
TL;DR: Vaccination of cattle with proteins secreted by E. coli O157:H7 significantly reduced the numbers of bacteria shed in feces, the number of animals that shed, and the duration of shedding in an experimental challenge model, suggesting it is possible to vaccinate cattle to decrease the level of E. bacteria shed for the purpose of reducing the risk of human disease.

319 citations


Journal ArticleDOI
23 Jun 2004-Vaccine
TL;DR: Results strongly suggest that PLGA nanoparticles provide an efficient vaccine delivery system for targeting DCs and the development of DC based cellular vaccines.

274 citations


Journal ArticleDOI
13 Aug 2004-Vaccine
TL;DR: It is suggested that addition of CPG 7909 to Fluarix may allow the use of reduced vaccine doses without reduced immunogenicity, and post-vaccination humoral immune responses were not significantly enhanced.

264 citations


Journal ArticleDOI
16 Dec 2004-Vaccine
TL;DR: The consultation unanimously agreed that additional clinical bridging studies as well as studies to clarify local epidemiology should be conducted in certain developing countries to determine the potential impact of vaccination and stressed the importance of maintaining existing cervical screening programmes while long-term studies are conducted.

220 citations


Journal ArticleDOI
02 Jun 2004-Vaccine
TL;DR: The present knowledge on pneumococcal vaccines and the current status of novel vaccine strategies are discussed.

219 citations


Journal ArticleDOI
16 Dec 2004-Vaccine
TL;DR: Results encourage the development of an AMA1 vaccine based on the full-length ectodomain, and indicate that the function of human antibodies to allele-specific and conserved epitopes in AMA1 should be studied further.

211 citations


Journal ArticleDOI
07 May 2004-Vaccine
TL;DR: In conclusion, liposome bilayer composition has an important effect on interaction with DCs and might be critical for the vaccination outcome.

207 citations



Journal ArticleDOI
16 Apr 2004-Vaccine
TL;DR: Results indicate that pulmonary delivery of DNA vaccines against tuberculosis may provide an advantageous delivery route compared to intramuscular immunization, and that increased immunogenicity can be achieved by delivery of this DNA encapsulated in chitosan nanoparticles.

Journal ArticleDOI
22 Oct 2004-Vaccine
TL;DR: With an average yield of 172 mg of PA per plant using an experimental transgenic cultivar grown in a greenhouse, 400 million doses of vaccine could be produced per acre, a yield that could be further enhanced 18-fold using a commercial cultivar in the field.

Journal ArticleDOI
28 Sep 2004-Vaccine
TL;DR: Methane emissions from sheep immunized with an anti-methanogen vaccine were significantly lower than methane emissions from non-immunized sheep, and the effectiveness of two different vaccine formulations (VF) on methane abatement was tested, and methane emissions measured using a closed-circuit respiration chamber and the sulphur-hexafluoride tracer technique were compared.

Journal ArticleDOI
22 Oct 2004-Vaccine
TL;DR: Transgenic corn expressing 1 mg of LT-B of Escherichia coli without buffer was fed to adult volunteers in three doses, and seven of nine volunteers developed rises in both serum IgG anti-LT and numbers of specific antibody secreting cells after vaccination.

Journal ArticleDOI
22 Oct 2004-Vaccine
TL;DR: Conclusions on the cost-effectiveness of pneumococcal conjugate vaccine are sensitive to assumptions regarding the current burden of pneumonia among the elderly and the future impact that vaccination will have in the unvaccinated and on the future serotype distribution.

Journal ArticleDOI
Ali Fattom1, Gary Horwith1, Steve Fuller1, Myra Propst1, Robert B. Naso1 
17 Feb 2004-Vaccine
TL;DR: A conjugate vaccine that includes the two most prevalent capsular polysaccharides, types 5 and 8, coupled to a carrier protein efficient in promoting a Th2 response, was developed and was shown to prevent S. aureus bacteremia for up to 10 months following a single immunization.

Journal ArticleDOI
25 Nov 2004-Vaccine
TL;DR: The HPV16 Immunotherapeutic comprising HPV16E6E7 fusion protein and ISCOMATRIX adjuvant is safe and induces vaccine antigen specific cell mediated immunity for patients with CIN.

Journal ArticleDOI
03 Sep 2004-Vaccine
TL;DR: It remains undetermined if strain RB51 vaccine can cause systemic brucellosis in humans, and early culture attempts on those exposed and developing disease in the future and serologic diagnostic assays for anti-RB-51 antibodies are needed to define if these adverse events are due to RB51 and to define appropriate prophylaxis regimens.

Journal ArticleDOI
02 Jun 2004-Vaccine
TL;DR: It is suggested that exercise may enhance the mean fold increase in antibody titer in response to influenza immunization if the influenza antigen was contained in the previous year's vaccine.

Journal ArticleDOI
25 Feb 2004-Vaccine
TL;DR: Allowing pharmacists to provide vaccinations is associated with higher influenza vaccination rates for individuals aged 65 years and older.

Journal ArticleDOI
23 Jun 2004-Vaccine
TL;DR: The potency of an HIV DNA vaccine was enhanced in rhesus macaques by in vivo electroporation, as judged by increased onset, magnitude and duration of antibody and cell-mediated immune responses against both components of a combination Gag and Env vaccine.

Journal ArticleDOI
02 Jan 2004-Vaccine
TL;DR: Results suggested that the antibody response, as determined by the quantitative anti-rPA IgG ELISA and toxin neutralizing antibody (TNA) assay, were significant predictors of protection against a B. anthracis aerosol spore challenge in rabbits.

Journal ArticleDOI
12 Mar 2004-Vaccine
TL;DR: To ascertain the economic feasibility of a pediatric tetravalent dengue vaccine, a cost-effectiveness model of vaccinating children at 15 months in Southeast (SE) Asia using a societal perspective was developed and calibrated.

Journal ArticleDOI
12 Mar 2004-Vaccine
TL;DR: It is shown that different antigens can be successfully presented on the spore coat and supports the use of the spores as an efficient vehicle for mucosal immunisation.

Journal ArticleDOI
23 Jun 2004-Vaccine
TL;DR: Over a 24 h period, liquid phage suspensions were stable within the pH range pH 3-11, therefore oral administration of bacteriophage DNA vaccines via drinking water may be possible.

Journal ArticleDOI
02 Jun 2004-Vaccine
TL;DR: Here, glutamate and aspartate increase correlated to virus release kinetics, indicating cell disruption and apoptosis, andabolite concentration profiles for glucose, glutamine, lactate and ammonium were always below inhibiting levels.

Journal ArticleDOI
17 Feb 2004-Vaccine
TL;DR: The development of an enterococcal vaccine based on capsular polysaccharides may improve the ability to prevent and treat these infections and the search for alternative treatment and preventive options is important.

Journal ArticleDOI
09 Sep 2004-Vaccine
TL;DR: The results of this study suggest that there is a lack of cross-protection of S. iniae bacterins against S. agalactiae modified bacterin vaccine in tilapia regardless of whether the fish were immunized and challenged at 26 or 32 degrees C.

Journal ArticleDOI
29 Mar 2004-Vaccine
TL;DR: Protection experiment showed that chicken immunization with avirulent Salmonella carrying Campylobacter cjaA gene greatly reduced the ability of heterologous wild type C. jejuni strain to colonize the bird cecum.